Gastroenterology
Conference Coverage
TNF blockers not associated with poorer pregnancy outcomes
Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal...
Commentary
The steep costs of disrupting gut-barrier harmony
When the gut barrier is disrupted by factors such as infection, low-fiber diet, antibiotics, and alcohol, then it cannot function normally to...
Latest News
Review estimates acne risk with JAK inhibitor therapy
Acne has been reported to be an adverse effect of JAK inhibitors, but not much is known about how common acne is overall.
Conference Coverage
Popular liver supplements lack data supporting efficacy, study shows
“But our research revealed that strong scientific evidence supporting the efficacy of any of these supplements is currently lacking.”
News from the FDA/CDC
FDA OKs new treatment for erosive esophagitis
Vonoprazan provides clinicians with a “new first-in-class therapeutic option that demonstrated faster healing in the more difficult-to-treat GERD...
Sponsored Supplement
Getting to Goal: How Thiazide-Type Diuretics, Following the Guidelines, and Improving Patient Adherence Can Help
Conference Coverage
Gut microbiome variations may be predictive of precancerous colonic lesions, CRC
“We really need to find new predictors of tumorigenesis. We already have some good predictors, mainly FIT, but these are not enough. These gut...
From the Journals
Does diabetes affect colorectal cancer outcomes?
“Preventing diabetes complications may help improve survival in patients with CRC, especially [in] female patients and those in the early stages...
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.
Commentary
GI symptoms during menopause deserve attention
We must do a better job about individualizing care. Rather than treating patients as disease states, we must start to do specific patient-focused...
Conference Coverage
Dupilumab promising for children aged 1-11 with EoE
Dupilumab was recently approved for adult EOE. It’s been shown to have a good safety profile in adults.